{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:44:31Z","timestamp":1791211471653,"version":"4.1.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK125513"],"award-info":[{"award-number":["DK125513"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK125513"],"award-info":[{"award-number":["DK125513"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK125513"],"award-info":[{"award-number":["DK125513"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lipodystrophy Research Fund at University of Michigan"},{"name":"Caswell Diabetes Institute of University of Michigan"},{"name":"Rejuvenate Bio"},{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review aims to introduce the latest developments in etiology and classification of lipodystrophy syndromes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Recent developments in genetic assessment with deeper sequencing have increased the number of specific etiologies of lipodystrophy with known single-gene associations. Despite this, more than 50% of patients diagnosed with partial and most of acquired lipodystrophy do not have a precise disease mechanism. Regardless of the cause of lipodystrophy, patients present with multiple important comorbidities. Complications impact not only metabolic endpoints but the entire body, akin to what happens in extreme obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>As research advances, new subtypes of lipodystrophy are being identified, with recent studies shifting focus from adipocyte differentiation to the role of cellular structures, survival pathways, and immune regulation in the disease etiology. These metabolic diseases pose significant clinical challenges, underscoring the need for further research to understand the mechanisms more precisely, identify new subtypes, and develop targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11892-025-01602-5","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T02:43:00Z","timestamp":1755744180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lipodystrophy Syndromes: One Name but Many Diseases Highlighting the Importance of Adipose Tissue in Metabolism"],"prefix":"10.1007","volume":"25","author":[{"given":"Maria","family":"Foss-Freitas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Gilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif A.","family":"Oral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"12","key":"1602_CR1","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1210\/jc.2016-2466","volume":"101","author":"RJ Brown","year":"2016","unstructured":"Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and management of lipodystrophy syndromes: A Multi-Society practice guideline. J Clin Endocrinol Metab. 2016;101(12):4500\u201311.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1602_CR2","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"Garg A. Clinical review#: lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313\u201325.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1602_CR3","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1210\/jc.2018-02730","volume":"104","author":"B Akinci","year":"2019","unstructured":"Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, et al. Comorbidities and survival in patients with lipodystrophy: an international chart review study. J Clin Endocrinol Metab. 2019;104(11):5120\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1602_CR4","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/cen.13311","volume":"86","author":"N Ajluni","year":"2017","unstructured":"Ajluni N, Meral R, Neidert AH, Brady GF, Buras E, McKenna B, et al. Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort. Clin Endocrinol (Oxf). 2017;86(5):698\u2013707.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1602_CR5","unstructured":"Ajluni N, Dar M, Xu J, Neidert AH, Oral EA. Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program. J Diabetes Metab 2016;7(3)."},{"issue":"7","key":"1602_CR6","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1210\/jc.2016-1005","volume":"101","author":"B Akinci","year":"2016","unstructured":"Akinci B, Onay H, Demir T, Ozen S, Kayserili H, Akinci G, et al. Natural history of congenital generalized lipodystrophy: A nationwide study from Turkey. J Clin Endocrinol Metab. 2016;101(7):2759\u201367.","journal-title":"J Clin Endocrinol Metab"},{"key":"1602_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.metabol.2017.04.010","volume":"72","author":"B Akinci","year":"2017","unstructured":"Akinci B, Onay H, Demir T, Savas-Erdeve \u015e, Gen R, Simsir IY, et al. Clinical presentations, metabolic abnormalities and end-organ complications in patients with Familial partial lipodystrophy. Metabolism. 2017;72:109\u201319.","journal-title":"Metabolism"},{"issue":"9","key":"1602_CR8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.metabol.2015.06.004","volume":"64","author":"B Akinci","year":"2015","unstructured":"Akinci B, Koseoglu FD, Onay H, Yavuz S, Altay C, Simsir IY, et al. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. Metabolism. 2015;64(9):1086\u201395.","journal-title":"Metabolism"},{"issue":"1\u20132","key":"1602_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1080\/07435800.2018.1513029","volume":"44","author":"B Ozgen Saydam","year":"2019","unstructured":"Ozgen Saydam B, Sonmez M, Simsir IY, Erturk MS, Kulaksizoglu M, Arkan T, et al. A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities. Endocr Res. 2019;44(1\u20132):46\u201354.","journal-title":"Endocr Res"},{"issue":"12","key":"1602_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11892-018-1099-9","volume":"18","author":"B Akinci","year":"2018","unstructured":"Akinci B, Meral R, Oral EA. Phenotypic and genetic characteristics of lipodystrophy: pathophysiology, metabolic abnormalities, and comorbidities. Curr Diab Rep. 2018;18(12):143.","journal-title":"Curr Diab Rep"},{"issue":"5","key":"1602_CR11","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1042\/BCJ20190468","volume":"477","author":"A Yang","year":"2020","unstructured":"Yang A, Mottillo EP. Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics. Biochem J. 2020;477(5):985\u20131008.","journal-title":"Biochem J"},{"key":"1602_CR12","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Garc\u00eda C, S\u00e1nchez-Quesada C, Mart\u00ednez-Ram\u00edrez MJ, Gaforio JJ. PPAR\u03b3 gene as a possible link between acquired and congenital lipodystrophy and its modulation by dietary fatty acids. Nutrients. 2022;14(22).","DOI":"10.3390\/nu14224742"},{"issue":"1","key":"1602_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/19491034.2018.1456217","volume":"9","author":"C Vigouroux","year":"2018","unstructured":"Vigouroux C, Gu\u00e9nantin AC, Vatier C, Capel E, Le Dour C, Afonso P, et al. Lipodystrophic syndromes due to LMNA mutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives. Nucleus. 2018;9(1):235\u201348.","journal-title":"Nucleus"},{"issue":"2","key":"1602_CR14","doi-asserted-by":"publisher","first-page":"a000760","DOI":"10.1101\/cshperspect.a000760","volume":"2","author":"HJ Worman","year":"2010","unstructured":"Worman HJ, Ostlund C, Wang Y. Diseases of the nuclear envelope. Cold Spring Harb Perspect Biol. 2010;2(2):a000760.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1602_CR15","doi-asserted-by":"crossref","unstructured":"Gauthier BR, Comaills V. Nuclear envelope integrity in health and disease: consequences on genome instability and inflammation. Int J Mol Sci. 2021;22(14).","DOI":"10.3390\/ijms22147281"},{"issue":"3","key":"1602_CR16","doi-asserted-by":"publisher","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","volume":"320","author":"T Kawai","year":"2021","unstructured":"Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375\u201391.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1602_CR17","unstructured":"Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E et al. Endotext. 2000."},{"issue":"2","key":"1602_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/17446651.2020.1735360","volume":"15","author":"MC Foss-Freitas","year":"2020","unstructured":"Foss-Freitas MC, Akinci B, Luo Y, Stratton A, Oral EA. Diagnostic strategies and clinical management of lipodystrophy. Expert Rev Endocrinol Metab. 2020;15(2):95\u2013114.","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"6","key":"1602_CR19","doi-asserted-by":"publisher","first-page":"e0199052","DOI":"10.1371\/journal.pone.0199052","volume":"13","author":"JG Lima","year":"2018","unstructured":"Lima JG, Nobrega LHC, Lima NN, Dos Santos MCF, Silva PHD, Baracho MFP, et al. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy. PLoS ONE. 2018;13(6):e0199052.","journal-title":"PLoS ONE"},{"key":"1602_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13098-017-0280-7","volume":"9","author":"LB de Azevedo Medeiros","year":"2017","unstructured":"de Azevedo Medeiros LB, C\u00e2ndido Dantas VK, Craveiro Sarmento AS, Agnez-Lima LF, Meireles AL, Xavier Nobre TT, et al. High prevalence of Berardinelli-Seip congenital lipodystrophy in Rio Grande do Norte state, Northeast Brazil. Diabetol Metab Syndr. 2017;9:80.","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"1602_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1210\/jcem-14-2-193","volume":"14","author":"BERARDINELLI W","year":"1954","unstructured":"BERARDINELLI W. An undiagnosed endocrinometabolic syndrome: report of 2 cases. J Clin Endocrinol Metab. 1954;14(2):193\u2013204.","journal-title":"J Clin Endocrinol Metab"},{"key":"1602_CR22","doi-asserted-by":"crossref","unstructured":"SEIP M. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? Acta Paediatr (Stockh). 1959;48:555\u201374.","DOI":"10.1111\/j.1651-2227.1959.tb16421.x"},{"issue":"12","key":"1602_CR23","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMra025261","volume":"350","author":"A Garg","year":"2004","unstructured":"Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350(12):1220\u201334.","journal-title":"N Engl J Med"},{"issue":"52","key":"1602_CR24","doi-asserted-by":"publisher","first-page":"e2312666120","DOI":"10.1073\/pnas.2312666120","volume":"120","author":"I Sakuma","year":"2023","unstructured":"Sakuma I, Gaspar RC, Luukkonen PK, Kahn M, Zhang D, Zhang X, et al. Lysophosphatidic acid triggers inflammation in the liver and white adipose tissue in rat models of 1-acyl-sn-glycerol-3-phosphate acyltransferase 2 deficiency and overnutrition. Proc Natl Acad Sci U S A. 2023;120(52):e2312666120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1602_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/MD.0b013e3181e9442f","volume":"89","author":"BC Lupsa","year":"2010","unstructured":"Lupsa BC, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment. Med (Baltim). 2010;89(4):245\u201350.","journal-title":"Med (Baltim)"},{"issue":"9","key":"1602_CR26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nrendo.2015.123","volume":"11","author":"N Patni","year":"2015","unstructured":"Patni N, Garg A. Congenital generalized lipodystrophies\u2013new insights into metabolic dysfunction. Nat Rev Endocrinol. 2015;11(9):522\u201334.","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"1602_CR27","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1210\/jc.2003-030855","volume":"88","author":"AK Agarwal","year":"2003","unstructured":"Agarwal AK, Simha V, Oral EA, Moran SA, Gorden P, O\u2019Rahilly S, et al. Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab. 2003;88(10):4840\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1602_CR28","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.cmet.2024.01.011","volume":"36","author":"S Rong","year":"2024","unstructured":"Rong S, Xia M, Vale G, Wang S, Kim CW, Li S, et al. DGAT2 Inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER. Cell Metab. 2024;36(3):617\u2013e297.","journal-title":"Cell Metab"},{"issue":"6","key":"1602_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/jmedgenet-2013-101525","volume":"50","author":"E Guill\u00e9n-Navarro","year":"2013","unstructured":"Guill\u00e9n-Navarro E, S\u00e1nchez-Iglesias S, Domingo-Jim\u00e9nez R, Victoria B, Ruiz-Riquelme A, R\u00e1bano A, et al. A new seipin-associated neurodegenerative syndrome. J Med Genet. 2013;50(6):401\u20139.","journal-title":"J Med Genet"},{"key":"1602_CR30","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Iglesias S, Fern\u00e1ndez-Pombo A, Cobelo-G\u00f3mez S, Hermida-Ameijeiras \u00c1, Alarc\u00f3n-Mart\u00ednez H, Domingo-Jim\u00e9nez R et al. Celia\u2019s Encephalopathy (BSCL2-Gene-Related): Current Understanding. J Clin Med. 2021;10(7).","DOI":"10.3390\/jcm10071435"},{"issue":"4","key":"1602_CR31","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1210\/jc.2007-1328","volume":"93","author":"CA Kim","year":"2008","unstructured":"Kim CA, Del\u00e9pine M, Boutet E, El Mourabit H, Le Lay S, Meier M, et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab. 2008;93(4):1129\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1602_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1530\/EJE-21-0915","volume":"185","author":"AN Karhan","year":"2021","unstructured":"Karhan AN, Zammouri J, Auclair M, Capel E, Apaydin FD, Ates F, et al. Biallelic CAV1 null variants induce congenital generalized lipodystrophy with achalasia. Eur J Endocrinol. 2021;185(6):841\u201354.","journal-title":"Eur J Endocrinol"},{"key":"1602_CR33","doi-asserted-by":"publisher","first-page":"1212729","DOI":"10.3389\/fendo.2023.1212729","volume":"14","author":"V Mancioppi","year":"2023","unstructured":"Mancioppi V, Daffara T, Romanisio M, Ceccarini G, Pelosini C, Santini F, et al. A new mutation in the. Front Endocrinol (Lausanne). 2023;14:1212729.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"1602_CR34","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1172\/JCI38660","volume":"119","author":"YK Hayashi","year":"2009","unstructured":"Hayashi YK, Matsuda C, Ogawa M, Goto K, Tominaga K, Mitsuhashi S, et al. Human PTRF mutations cause secondary deficiency of Caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest. 2009;119(9):2623\u201333.","journal-title":"J Clin Invest"},{"issue":"3","key":"1602_CR35","doi-asserted-by":"publisher","first-page":"e1000874","DOI":"10.1371\/journal.pgen.1000874","volume":"6","author":"A Rajab","year":"2010","unstructured":"Rajab A, Straub V, McCann LJ, Seelow D, Varon R, Barresi R, et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 2010;6(3):e1000874.","journal-title":"PLoS Genet"},{"issue":"6","key":"1602_CR36","doi-asserted-by":"publisher","first-page":"e63533","DOI":"10.1002\/ajmg.a.63533","volume":"194","author":"G Akinci","year":"2024","unstructured":"Akinci G, Alyaarubi S, Patni N, Alhashmi N, Al-Shidhani A, Prodam F, et al. Metabolic and other morbid complications in congenital generalized lipodystrophy type 4. Am J Med Genet A. 2024;194(6):e63533.","journal-title":"Am J Med Genet A"},{"issue":"6404","key":"1602_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(46)91599-1","volume":"1","author":"RD Lawrence","year":"1946","unstructured":"Lawrence RD. Lipodystrophy and hepatomegaly with diabetes, lipaemia, and other metabolic disturbances; a case throwing new light on the action of insulin. (concluded). Lancet. 1946;1(6404):773.","journal-title":"Lancet"},{"issue":"2","key":"1602_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00005792-200303000-00007","volume":"82","author":"A Misra","year":"2003","unstructured":"Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Med (Baltim). 2003;82(2):129\u201346.","journal-title":"Med (Baltim)"},{"issue":"3","key":"1602_CR39","doi-asserted-by":"publisher","first-page":"104073","DOI":"10.1016\/j.lpm.2021.104073","volume":"50","author":"G Ceccarini","year":"2021","unstructured":"Ceccarini G, Magno S, Gilio D, Pelosini C, Santini F. Autoimmunity in lipodystrophy syndromes. Presse Med. 2021;50(3):104073.","journal-title":"Presse Med"},{"issue":"1","key":"1602_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1210\/jc.2008-1703","volume":"94","author":"DB Savage","year":"2009","unstructured":"Savage DB, Semple RK, Clatworthy MR, Lyons PA, Morgan BP, Cochran EK, et al. Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab. 2009;94(1):10\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"1602_CR41","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.3389\/fimmu.2018.02142","volume":"9","author":"F Corvillo","year":"2018","unstructured":"Corvillo F, Aparicio V, L\u00f3pez-Lera A, Garrido S, Ara\u00fajo-Vilar D, de Miguel MP, et al. Autoantibodies against perilipin 1 as a cause of acquired generalized lipodystrophy. Front Immunol. 2018;9:2142.","journal-title":"Front Immunol"},{"issue":"1","key":"1602_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2337\/db21-1172","volume":"72","author":"C Mandel-Brehm","year":"2023","unstructured":"Mandel-Brehm C, Vazquez SE, Liverman C, Cheng M, Quandt Z, Kung AF, et al. Autoantibodies to Perilipin-1 define a subset of acquired generalized lipodystrophy. Diabetes. 2023;72(1):59\u201370.","journal-title":"Diabetes"},{"issue":"1","key":"1602_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2337\/db21-1086","volume":"72","author":"F Corvillo","year":"2023","unstructured":"Corvillo F, Abel BS, L\u00f3pez-Lera A, Ceccarini G, Magno S, Santini F, et al. Characterization and clinical association of autoantibodies against perilipin 1 in patients with acquired generalized lipodystrophy. Diabetes. 2023;72(1):71\u201384.","journal-title":"Diabetes"},{"issue":"8","key":"1602_CR44","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2018-00494","volume":"103","author":"B Halpern","year":"2018","unstructured":"Halpern B, Nery M, Pereira MAA. Case report of acquired generalized lipodystrophy associated with common variable immunodeficiency. J Clin Endocrinol Metab. 2018;103(8):2807\u201310.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1602_CR45","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/j.amjmed.2017.04.035","volume":"130","author":"J Cunningham","year":"2017","unstructured":"Cunningham J, Nadal R, Broome C. Acquired generalized lipodystrophy following immune thrombocytopenia. Am J Med. 2017;130(10):e445\u20136.","journal-title":"Am J Med"},{"key":"1602_CR46","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3389\/fimmu.2018.01715","volume":"9","author":"C Le Coz","year":"2018","unstructured":"Le Coz C, Nolan BE, Trofa M, Kamsheh AM, Khokha MK, Lakhani SA, et al. Cytotoxic T-Lymphocyte-Associated protein 4 Haploinsufficiency-Associated inflammation can occur independently of T-Cell hyperproliferation. Front Immunol. 2018;9:1715.","journal-title":"Front Immunol"},{"issue":"2","key":"1602_CR47","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bjd.18124","volume":"182","author":"N Haddad","year":"2020","unstructured":"Haddad N, Vidal-Trecan T, Baroudjian B, Zagdanski AM, Arangalage D, Battistella M, et al. Acquired generalized lipodystrophy under immune checkpoint Inhibition. Br J Dermatol. 2020;182(2):477\u201380.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1602_CR48","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.2337\/dc18-2535","volume":"42","author":"A Jehl","year":"2019","unstructured":"Jehl A, Cugnet-Anceau C, Vigouroux C, Legeay AL, Dalle S, Harou O, et al. Acquired generalized lipodystrophy: A new cause of Anti-PD-1 Immune-Related diabetes. Diabetes Care. 2019;42(10):2008\u201310.","journal-title":"Diabetes Care"},{"issue":"6","key":"1602_CR49","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/CMR.0000000000000660","volume":"30","author":"SS Gnanendran","year":"2020","unstructured":"Gnanendran SS, Miller JA, Archer CA, Jain SV, Hwang SJE, Peters G, et al. Acquired lipodystrophy associated with immune checkpoint inhibitors. Melanoma Res. 2020;30(6):599\u2013602.","journal-title":"Melanoma Res"},{"issue":"1","key":"1602_CR50","first-page":"e40","volume":"6","author":"S Bedrose","year":"2020","unstructured":"Bedrose S, Turin CG, Lavis VR, Kim ST, Thosani SN, A CASE OF ACQUIRED, GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA. AACE Clin Case Rep. 2020;6(1):e40\u20135.","journal-title":"AACE Clin Case Rep"},{"issue":"8","key":"1602_CR51","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1210\/jc.2018-02221","volume":"104","author":"CK Falcao","year":"2019","unstructured":"Falcao CK, Cabral MCS, Mota JM, Arbache ST, Costa-Riquetto AD, Muniz DQB, et al. Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma. J Clin Endocrinol Metab. 2019;104(8):3245\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1602_CR52","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1001\/archderm.1987.01660360090018","volume":"123","author":"JK Billings","year":"1987","unstructured":"Billings JK, Milgraum SS, Gupta AK, Headington JT, Rasmussen JE. Lipoatrophic panniculitis: a possible autoimmune inflammatory disease of fat. Report of three cases. Arch Dermatol. 1987;123(12):1662\u20136.","journal-title":"Arch Dermatol"},{"issue":"2","key":"1602_CR53","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/MD.0b013e31816bc604","volume":"87","author":"A Bingham","year":"2008","unstructured":"Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Med (Baltim). 2008;87(2):70\u201386.","journal-title":"Med (Baltim)"},{"issue":"3","key":"1602_CR54","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1210\/jc.2017-02078","volume":"103","author":"I Hussain","year":"2018","unstructured":"Hussain I, Patni N, Ueda M, Sorkina E, Valerio CM, Cochran E, et al. A novel generalized Lipodystrophy-Associated progeroid syndrome due to recurrent heterozygous LMNA p.T10I mutation. J Clin Endocrinol Metab. 2018;103(3):1005\u201314.","journal-title":"J Clin Endocrinol Metab"},{"key":"1602_CR55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40842-018-0058-3","volume":"4","author":"M Sahinoz","year":"2018","unstructured":"Sahinoz M, Khairi S, Cuttitta A, Brady GF, Rupani A, Meral R, et al. Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis. Clin Diabetes Endocrinol. 2018;4:6.","journal-title":"Clin Diabetes Endocrinol"},{"issue":"4","key":"1602_CR56","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1210\/jc.2015-3722","volume":"101","author":"E Sorkina","year":"2016","unstructured":"Sorkina E, Frolova E, Rusinova D, Polyakova S, Roslavtseva E, Vasilyev E, et al. Progressive generalized lipodystrophy as a manifestation of autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab. 2016;101(4):1344\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"1602_CR57","unstructured":"Akinci B, Sahinoz M, Oral E. Lipodystrophy syndromes: presentation and treatment. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al. editors. Endotext. South Dartmouth (MA): mdtext.com, inc. Copyright \u00a9 2000\u20132024. MDText.com, Inc.; 2000."},{"key":"1602_CR58","doi-asserted-by":"publisher","first-page":"1359211","DOI":"10.3389\/fendo.2024.1359211","volume":"15","author":"NR Guidorizzi","year":"2024","unstructured":"Guidorizzi NR, Valerio CM, Viola LF, Veras VR, Fernandes VO, Lima GEDC, et al. Comprehensive analysis of morbidity and mortality patterns in Familial partial lipodystrophy patients: insights from a population study. Front Endocrinol (Lausanne). 2024;15:1359211.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1602_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng.3714","volume":"49","author":"LA Lotta","year":"2017","unstructured":"Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49(1):17\u201326.","journal-title":"Nat Genet"},{"issue":"7","key":"1602_CR60","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2337\/dbi24-0018","volume":"73","author":"B Akinci","year":"2024","unstructured":"Akinci B, von Schnurbein J, Araujo-Vilar D, Wabitsch M, Oral EA. Lipodystrophy prevalence, Lipodystrophy-Like phenotypes, and diagnostic challenges. Diabetes. 2024;73(7):1039\u201342.","journal-title":"Diabetes"},{"key":"1602_CR61","doi-asserted-by":"publisher","first-page":"116137","DOI":"10.1016\/j.bcp.2024.116137","volume":"223","author":"A Bavaresco","year":"2024","unstructured":"Bavaresco A, Mazzeo P, Lazzara M, Barbot M. Adipose tissue in cortisol excess: what cushing\u2019s syndrome can teach us? Biochem Pharmacol. 2024;223:116137.","journal-title":"Biochem Pharmacol"},{"key":"1602_CR62","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2147\/DMSO.S206053","volume":"13","author":"C Bagias","year":"2020","unstructured":"Bagias C, Xiarchou A, Bargiota A, Tigas S. Familial partial lipodystrophy (FPLD): recent insights. Diabetes Metab Syndr Obes. 2020;13:1531\u201344.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"1602_CR63","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41591-024-02865-3","volume":"30","author":"K Smith","year":"2024","unstructured":"Smith K, Deutsch AJ, McGrail C, Kim H, Hsu S, Huerta-Chagoya A, et al. Multi-ancestry polygenic mechanisms of type 2 diabetes. Nat Med. 2024;30(4):1065\u201374.","journal-title":"Nat Med"},{"issue":"9","key":"1602_CR64","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11892-022-01485-w","volume":"22","author":"N Patni","year":"2022","unstructured":"Patni N, Garg A. Lipodystrophy for the Diabetologist-What to look for. Curr Diab Rep. 2022;22(9):461\u201370.","journal-title":"Curr Diab Rep"},{"issue":"4","key":"1602_CR65","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1210\/jc.2018-01922","volume":"104","author":"N Patni","year":"2019","unstructured":"Patni N, Li X, Adams-Huet B, Vasandani C, Gomez-Diaz RA, Garg A. Regional body fat changes and metabolic complications in children with Dunnigan Lipodystrophy-Causing LMNA variants. J Clin Endocrinol Metab. 2019;104(4):1099\u2013108.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1602_CR66","first-page":"1776","volume":"85","author":"A Garg","year":"2000","unstructured":"Garg A. Gender differences in the prevalence of metabolic complications in Familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 2000;85(5):1776\u201382.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1602_CR67","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.2337\/diacare.26.5.1350","volume":"26","author":"WA Haque","year":"2003","unstructured":"Haque WA, Oral EA, Dietz K, Bowcock AM, Agarwal AK, Garg A. Risk factors for diabetes in Familial partial lipodystrophy, Dunnigan variety. Diabetes Care. 2003;26(5):1350\u20135.","journal-title":"Diabetes Care"},{"issue":"6","key":"1602_CR68","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/cen.14426","volume":"94","author":"AJ Eldin","year":"2021","unstructured":"Eldin AJ, Akinci B, da Rocha AM, Meral R, Simsir IY, Adiyaman SC, et al. Cardiac phenotype in Familial partial lipodystrophy. Clin Endocrinol (Oxf). 2021;94(6):1043\u201353.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1602_CR69","first-page":"305","volume":"114","author":"MMD Romano","year":"2020","unstructured":"Romano MMD, Chacon PAI, Ramalho FNZ, Foss MC, Schmidt A. Cardiac alterations in patients with Familial lipodystrophy. Arq Bras Cardiol. 2020;114(2):305\u201312.","journal-title":"Arq Bras Cardiol"},{"issue":"6","key":"1602_CR70","first-page":"e20230442","volume":"121","author":"MMD Romano","year":"2024","unstructured":"Romano MMD, Sapalo AT, Guidorizzi NR, Moreira HT, In\u00eas PAC, Kalil LC, et al. Echocardiographic alterations of cardiac geometry and function in patients with Familial partial lipodystrophy. Arq Bras Cardiol. 2024;121(6):e20230442.","journal-title":"Arq Bras Cardiol"},{"key":"1602_CR71","doi-asserted-by":"crossref","unstructured":"Stiekema M, van Zandvoort MAMJ, Ramaekers FCS, Broers JLV. Structural and mechanical aberrations of the nuclear lamina in disease. Cells. 2020;9(8).","DOI":"10.3390\/cells9081884"},{"issue":"3","key":"1602_CR72","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1210\/clinem\/dgad606","volume":"109","author":"O Besci","year":"2024","unstructured":"Besci O, Foss de Freitas MC, Guidorizzi NR, Guler MC, Gilio D, Maung JN, et al. Deciphering the clinical presentations in LMNA-related lipodystrophy: report of 115 cases and a systematic review. J Clin Endocrinol Metab. 2024;109(3):e1204\u201324.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1602_CR73","doi-asserted-by":"publisher","first-page":"327","DOI":"10.5483\/BMBRep.2018.51.7.113","volume":"51","author":"SM Kang","year":"2018","unstructured":"Kang SM, Yoon MH, Park BJ. Laminopathies; mutations on single gene and various human genetic diseases. BMB Rep. 2018;51(7):327\u201337.","journal-title":"BMB Rep"},{"key":"1602_CR74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/ijms22168974","volume":"22","author":"C Sun","year":"2021","unstructured":"Sun C, Mao S, Chen S, Zhang W, Liu C. PPARs-Orchestrated metabolic homeostasis in the adipose tissue. Int J Mol Sci. 2021;22:16.","journal-title":"Int J Mol Sci"},{"key":"1602_CR75","doi-asserted-by":"publisher","first-page":"803189","DOI":"10.3389\/fendo.2021.803189","volume":"12","author":"J Zammouri","year":"2021","unstructured":"Zammouri J, Vatier C, Capel E, Auclair M, Storey-London C, Bismuth E, et al. Molecular and cellular bases of lipodystrophy syndromes. Front Endocrinol (Lausanne). 2021;12:803189.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"1602_CR76","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/ng.3700","volume":"48","author":"AR Majithia","year":"2016","unstructured":"Majithia AR, Tsuda B, Agostini M, Gnanapradeepan K, Rice R, Peloso G, et al. Prospective functional classification of all possible missense variants in PPARG. Nat Genet. 2016;48(12):1570\u20135.","journal-title":"Nat Genet"},{"issue":"12","key":"1602_CR77","doi-asserted-by":"publisher","first-page":"bvac155","DOI":"10.1210\/jendso\/bvac155","volume":"6","author":"C Vasandani","year":"2022","unstructured":"Vasandani C, Li X, Sekizkardes H, Brown RJ, Garg A. Phenotypic differences among Familial partial lipodystrophy due to LMNA or PPARG variants. J Endocr Soc. 2022;6(12):bvac155.","journal-title":"J Endocr Soc"},{"issue":"10 Pt B","key":"1602_CR78","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.bbalip.2017.07.009","volume":"1862","author":"C Sztalryd","year":"2017","unstructured":"Sztalryd C, Brasaemle DL. The perilipin family of lipid droplet proteins: gatekeepers of intracellular lipolysis. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(10 Pt B):1221\u201332.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"6","key":"1602_CR79","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1083\/jcb.200210169","volume":"161","author":"C Sztalryd","year":"2003","unstructured":"Sztalryd C, Xu G, Dorward H, Tansey JT, Contreras JA, Kimmel AR, et al. Perilipin A is essential for the translocation of hormone-sensitive lipase during lipolytic activation. J Cell Biol. 2003;161(6):1093\u2013103.","journal-title":"J Cell Biol"},{"issue":"9","key":"1602_CR80","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1210\/jc.2017-02662","volume":"103","author":"TW Laver","year":"2018","unstructured":"Laver TW, Patel KA, Colclough K, Curran J, Dale J, Davis N, et al. PLIN1 haploinsufficiency is not associated with lipodystrophy. J Clin Endocrinol Metab. 2018;103(9):3225\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1602_CR81","doi-asserted-by":"publisher","first-page":"e2318","DOI":"10.1210\/clinem\/dgac104","volume":"107","author":"KA Patel","year":"2022","unstructured":"Patel KA, Burman S, Laver TW, Hattersley AT, Frayling TM, Weedon MN. PLIN1 haploinsufficiency causes a favorable metabolic profile. J Clin Endocrinol Metab. 2022;107(6):e2318\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1602_CR82","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/jhg.2013.107","volume":"59","author":"T Nolis","year":"2014","unstructured":"Nolis T. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet. 2014;59(1):16\u201323.","journal-title":"J Hum Genet"},{"issue":"5","key":"1602_CR83","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/emmm.200900037","volume":"1","author":"O Rubio-Cabezas","year":"2009","unstructured":"Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple RK, Dash S, et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Mol Med. 2009;1(5):280\u20137.","journal-title":"EMBO Mol Med"},{"issue":"12","key":"1602_CR84","first-page":"1649","volume":"30","author":"SM Farhan","year":"2014","unstructured":"Farhan SM, Robinson JF, McIntyre AD, Marrosu MG, Ticca AF, Loddo S, et al. A novel LIPE nonsense mutation found using exome sequencing in siblings with late-onset Familial partial lipodystrophy. Can J Cardiol. 2014;30(12):1649\u201354.","journal-title":"Can J Cardiol"},{"issue":"1","key":"1602_CR85","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1212\/WNL.58.1.43","volume":"58","author":"JR Berger","year":"2002","unstructured":"Berger JR, Oral EA, Taylor SI. Familial lipodystrophy associated with neurodegeneration and congenital cataracts. Neurology. 2002;58(1):43\u20137.","journal-title":"Neurology"},{"issue":"8","key":"1602_CR86","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/ajmg.a.37115","volume":"167a","author":"A Garg","year":"2015","unstructured":"Garg A, Kircher M, Del Campo M, Amato RS, Agarwal AK. Whole exome sequencing identifies de Novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. Am J Med Genet A. 2015;167a(8):1796\u2013806.","journal-title":"Am J Med Genet A"},{"key":"1602_CR87","doi-asserted-by":"crossref","unstructured":"Garg A, Xing C, Agarwal AK, Westfall AK, Tomchick DR, Zhang X et al. Gain of function NOTCH3 variants cause Familial partial lipodystrophy due to activation of senescence pathways. Diabetes. 2024.","DOI":"10.2337\/figshare.27960534"},{"issue":"2","key":"1602_CR88","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.pathol.2018.11.004","volume":"51","author":"I Hussain","year":"2019","unstructured":"Hussain I, Patni N, Garg A. Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. Pathology. 2019;51(2):202\u201312.","journal-title":"Pathology"},{"issue":"9","key":"1602_CR89","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/14740338.2019.1644317","volume":"18","author":"C Lagathu","year":"2019","unstructured":"Lagathu C, B\u00e9r\u00e9ziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf. 2019;18(9):829\u201340.","journal-title":"Expert Opin Drug Saf"},{"issue":"17","key":"1602_CR90","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1097\/00002030-200311210-00005","volume":"17","author":"M Caron","year":"2003","unstructured":"Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J. Some HIV protease inhibitors alter lamin A\/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS. 2003;17(17):2437\u201344.","journal-title":"AIDS"},{"issue":"16","key":"1602_CR91","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1097\/00002030-200411050-00004","volume":"18","author":"M Caron","year":"2004","unstructured":"Caron M, Auclair M, Lagathu C, Lomb\u00e8s A, Walker UA, Kornprobst M, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and Zidovudine alter adipocyte functions in vitro. AIDS. 2004;18(16):2127\u201336.","journal-title":"AIDS"},{"issue":"1","key":"1602_CR92","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, et al. Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. 2023;8(1):207.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1602_CR93","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/ejcn.2014.149","volume":"69","author":"RA Beraldo","year":"2015","unstructured":"Beraldo RA, Vassimon HS, Aragon DC, Navarro AM, Albuquerque de Paula FJ, Foss-Freitas MC. Proposed ratios and cutoffs for the assessment of lipodystrophy in HIV-seropositive individuals. Eur J Clin Nutr. 2015;69(2):274\u20138.","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"1602_CR94","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2310\/6650.2005.00001","volume":"53","author":"WL Dinges","year":"2005","unstructured":"Dinges WL, Chen D, Snell PG, Weatherall PT, Peterson DM, Garg A. Regional body fat distribution in HIV-infected patients with lipodystrophy. J Investig Med. 2005;53(1):15\u201325.","journal-title":"J Investig Med"},{"issue":"2","key":"1602_CR95","doi-asserted-by":"publisher","first-page":"e0149905","DOI":"10.1371\/journal.pone.0149905","volume":"11","author":"RA Beraldo","year":"2016","unstructured":"Beraldo RA, Meliscki GC, Silva BR, Navarro AM, Bollela VR, Schmidt A, et al. Comparing the ability of anthropometric indicators in identifying metabolic syndrome in HIV patients. PLoS ONE. 2016;11(2):e0149905.","journal-title":"PLoS ONE"},{"issue":"6","key":"1602_CR96","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/ajcn\/nqy049","volume":"107","author":"RA Beraldo","year":"2018","unstructured":"Beraldo RA, Meliscki GC, Silva BR, Navarro AM, Bollela VR, Schmidt A, et al. Anthropometric measures of central adiposity are highly concordant with predictors of cardiovascular disease risk in HIV patients. Am J Clin Nutr. 2018;107(6):883\u201393.","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"1602_CR97","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1210\/jc.2002-020794","volume":"87","author":"D Chen","year":"2002","unstructured":"Chen D, Misra A, Garg A. Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab. 2002;87(11):4845\u201356.","journal-title":"J Clin Endocrinol Metab"},{"key":"1602_CR98","first-page":"123","volume":"16","author":"TA Lamesa","year":"2024","unstructured":"Lamesa TA. Biological depiction of lipodystrophy and its associated challenges among HIV AIDS patients. Literature Rev HIV AIDS (Auckl). 2024;16:123\u201332.","journal-title":"Literature Rev HIV AIDS (Auckl)"},{"issue":"3","key":"1602_CR99","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.amjms.2016.05.007","volume":"352","author":"JE Small","year":"2016","unstructured":"Small JE, Jassam YN, Small KM, Chea P, Popov V, Li S, et al. Barraquer-Simons syndrome. Am J Med Sci. 2016;352(3):280\u20134.","journal-title":"Am J Med Sci"},{"issue":"1","key":"1602_CR100","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","volume":"83","author":"A Misra","year":"2004","unstructured":"Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Med (Baltim). 2004;83(1):18\u201334.","journal-title":"Med (Baltim)"},{"issue":"2","key":"1602_CR101","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1086\/505885","volume":"79","author":"RA Hegele","year":"2006","unstructured":"Hegele RA, Cao H, Liu DM, Costain GA, Charlton-Menys V, Rodger NW, et al. Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy. Am J Hum Genet. 2006;79(2):383\u20139.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1602_CR102","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jaad.2006.05.005","volume":"55","author":"E Pope","year":"2006","unstructured":"Pope E, Janson A, Khambalia A, Feldman B. Childhood acquired lipodystrophy: a retrospective study. J Am Acad Dermatol. 2006;55(6):947\u201350.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1602_CR103","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13023-019-1292-1","volume":"15","author":"F Corvillo","year":"2020","unstructured":"Corvillo F, Ceccarini G, Nozal P, Magno S, Pelosini C, Garrido S, et al. Immunological features of patients affected by Barraquer-Simons syndrome. Orphanet J Rare Dis. 2020;15(1):9.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"1602_CR104","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJM197602262940902","volume":"294","author":"JG Sissons","year":"1976","unstructured":"Sissons JG, West RJ, Fallows J, Williams DG, Boucher BJ, Amos N, et al. The complement abnormalities of lipodystrophy. N Engl J Med. 1976;294(9):461\u20135.","journal-title":"N Engl J Med"},{"key":"1602_CR105","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.semcdb.2017.12.017","volume":"85","author":"A L\u00f3pez-Lera","year":"2019","unstructured":"L\u00f3pez-Lera A, Corvillo F, Nozal P, Regueiro JR, S\u00e1nchez-Corral P, L\u00f3pez-Trascasa M. Complement as a diagnostic tool in immunopathology. Semin Cell Dev Biol. 2019;85:86\u201397.","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"1602_CR106","first-page":"617","volume":"51","author":"Z Kurug\u00f6l","year":"2009","unstructured":"Kurug\u00f6l Z, Ulger Z, Berk O, Tu\u011fral O. Acquired partial lipodystrophy associated with varicella. Turk J Pediatr. 2009;51(6):617\u201320.","journal-title":"Turk J Pediatr"},{"issue":"1","key":"1602_CR107","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000249208","volume":"173","author":"JA Schifferli","year":"1986","unstructured":"Schifferli JA, Blanc E. Partial lipodystrophy, meningococcal meningitis and nephritis. Dermatologica. 1986;173(1):9\u201312.","journal-title":"Dermatologica"},{"issue":"4","key":"1602_CR108","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1297\/cpe.22.53","volume":"22","author":"M Adachi","year":"2013","unstructured":"Adachi M, Asakura Y, Muroya K, Goto H, Kigasawa H. Abnormal adipose tissue distribution with unfavorable metabolic profile in five children following hematopoietic stem cell transplantation: a new etiology for acquired partial lipodystrophy. Clin Pediatr Endocrinol. 2013;22(4):53\u201364.","journal-title":"Clin Pediatr Endocrinol"},{"issue":"11","key":"1602_CR109","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/pbc.25601","volume":"62","author":"C Wei","year":"2015","unstructured":"Wei C, Thyagiarajan MS, Hunt LP, Shield JP, Stevens MC, Crowne EC. Reduced insulin sensitivity in childhood survivors of Haematopoietic stem cell transplantation is associated with lipodystropic and sarcopenic phenotypes. Pediatr Blood Cancer. 2015;62(11):1992\u20139.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"1602_CR110","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1297\/cpe.26.99","volume":"26","author":"M Adachi","year":"2017","unstructured":"Adachi M, Oto Y, Muroya K, Hanakawa J, Asakura Y, Goto H. Partial lipodystrophy in patients who have undergone hematopoietic stem cell transplantation during childhood: an institutional cross-sectional survey. Clin Pediatr Endocrinol. 2017;26(2):99\u2013108.","journal-title":"Clin Pediatr Endocrinol"},{"issue":"11","key":"1602_CR111","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40618-017-0731-x","volume":"40","author":"G Ceccarini","year":"2017","unstructured":"Ceccarini G, Ferrari F, Santini F. Acquired partial lipodystrophy after bone marrow transplant during childhood: a novel syndrome to be added to the disease classification list. J Endocrinol Invest. 2017;40(11):1273\u20134.","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1602_CR112","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ajhg.2010.10.031","volume":"87","author":"AK Agarwal","year":"2010","unstructured":"Agarwal AK, Xing C, DeMartino GN, Mizrachi D, Hernandez MD, Sousa AB, et al. PSMB8 encoding the \u03b25i proteasome subunit is mutated in joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced lipodystrophy syndrome. Am J Hum Genet. 2010;87(6):866\u201372.","journal-title":"Am J Hum Genet"},{"issue":"10","key":"1602_CR113","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1172\/JCI58414","volume":"121","author":"A Kitamura","year":"2011","unstructured":"Kitamura A, Maekawa Y, Uehara H, Izumi K, Kawachi I, Nishizawa M, et al. A mutation in the Immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans. J Clin Invest. 2011;121(10):4150\u201360.","journal-title":"J Clin Invest"},{"issue":"3","key":"1602_CR114","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.33368","volume":"64","author":"Y Liu","year":"2012","unstructured":"Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, et al. Mutations in proteasome subunit \u03b2 type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum. 2012;64(3):895\u2013907.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1602_CR115","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/aps.2011.153","volume":"33","author":"KL Herbst","year":"2012","unstructured":"Herbst KL. Rare adipose disorders (RADs) masquerading as obesity. Acta Pharmacol Sin. 2012;33(2):155\u201372.","journal-title":"Acta Pharmacol Sin"},{"key":"1602_CR116","doi-asserted-by":"crossref","unstructured":"Rocha N, Bulger DA, Frontini A, Titheradge H, Gribsholt SB, Knox R et al. Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression. Elife. 2017;6.","DOI":"10.7554\/eLife.23813"},{"issue":"4","key":"1602_CR117","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.numecd.2015.01.010","volume":"25","author":"G Enzi","year":"2015","unstructured":"Enzi G, Busetto L, Sergi G, Coin A, Inelmen EM, Vindigni V, et al. Multiple symmetric lipomatosis: a rare disease and its possible links to brown adipose tissue. Nutr Metab Cardiovasc Dis. 2015;25(4):347\u201353.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"3","key":"1602_CR118","first-page":"551","volume":"52","author":"E Holme","year":"1993","unstructured":"Holme E, Larsson NG, Oldfors A, Tulinius M, Sahlin P, Stenman G. Multiple symmetric lipomas with high levels of MtDNA with the tRNA(Lys) A\u2013>G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am J Hum Genet. 1993;52(3):551\u20136.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1602_CR119","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1212\/WNL.51.1.258","volume":"51","author":"J G\u00e1mez","year":"1998","unstructured":"G\u00e1mez J, Play\u00e1n A, Andreu AL, Bruno C, Navarro C, Cervera C, et al. Familial multiple symmetric lipomatosis associated with the A8344G mutation of mitochondrial DNA. Neurology. 1998;51(1):258\u201360.","journal-title":"Neurology"},{"issue":"1","key":"1602_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00131402-200309000-00001","volume":"5","author":"PS Chong","year":"2003","unstructured":"Chong PS, Vucic S, Hedley-Whyte ET, Dreyer M, Cros D. Multiple symmetric lipomatosis (Madelung\u2019s Disease) caused by the MERRF (A8344G) mutation: A report of two cases and review of the literature. J Clin Neuromuscul Dis. 2003;5(1):1\u20137.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"5","key":"1602_CR121","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1212\/WNL.44.5.862","volume":"44","author":"T Klopstock","year":"1994","unstructured":"Klopstock T, Naumann M, Schalke B, Bischof F, Seibel P, Kottlors M, et al. Multiple symmetric lipomatosis: abnormalities in complex IV and multiple deletions in mitochondrial DNA. Neurology. 1994;44(5):862\u20136.","journal-title":"Neurology"},{"issue":"12","key":"1602_CR122","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1001\/archneurol.2009.284","volume":"66","author":"J Calvo","year":"2009","unstructured":"Calvo J, Funalot B, Ouvrier RA, Lazaro L, Toutain A, De Mas P, et al. Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by Mitofusin 2 mutations. Arch Neurol. 2009;66(12):1511\u20136.","journal-title":"Arch Neurol"},{"issue":"18","key":"1602_CR123","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1093\/hmg\/ddv229","volume":"24","author":"SL Sawyer","year":"2015","unstructured":"Sawyer SL, Cheuk-Him Ng A, Innes AM, Wagner JD, Dyment DA, Tetreault M, et al. Homozygous mutations in MFN2 cause multiple symmetric lipomatosis associated with neuropathy. Hum Mol Genet. 2015;24(18):5109\u201314.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"1602_CR124","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/jns.12117","volume":"20","author":"AS Carr","year":"2015","unstructured":"Carr AS, Polke JM, Wilson J, Pelayo-Negro AL, Laura M, Nanji T, et al. MFN2 deletion of exons 7 and 8: founder mutation in the UK population. J Peripher Nerv Syst. 2015;20(2):67\u201371.","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"1602_CR125","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamaneurol.2014.629","volume":"71","author":"F Bombelli","year":"2014","unstructured":"Bombelli F, Stojkovic T, Dubourg O, Echaniz-Laguna A, Tardieu S, Larcher K, et al. Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features. JAMA Neurol. 2014;71(8):1036\u201342.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1602_CR126","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/ng1341","volume":"36","author":"S Z\u00fcchner","year":"2004","unstructured":"Z\u00fcchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al. Mutations in the mitochondrial GTPase Mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 2004;36(5):449\u201351.","journal-title":"Nat Genet"},{"issue":"3","key":"1602_CR127","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1089\/ars.2007.1934","volume":"10","author":"OM de Brito","year":"2008","unstructured":"de Brito OM, Scorrano L. Mitofusin 2: a mitochondria-shaping protein with signaling roles beyond fusion. Antioxid Redox Signal. 2008;10(3):621\u201333.","journal-title":"Antioxid Redox Signal"},{"key":"1602_CR128","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3389\/fphys.2020.00782","volume":"11","author":"GW Dorn","year":"2020","unstructured":"Dorn GW 2. Mitofusin 2 dysfunction and disease in mice and men. Front Physiol. 2020;11:782.","journal-title":"Front Physiol"},{"key":"1602_CR129","doi-asserted-by":"crossref","unstructured":"Cohen MM, Tareste D. Recent insights into the structure and function of Mitofusins in mitochondrial fusion. F1000Res. 2018;7.","DOI":"10.12688\/f1000research.16629.1"},{"issue":"Pt 14","key":"1602_CR130","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1242\/jcs.02449","volume":"118","author":"S Honda","year":"2005","unstructured":"Honda S, Aihara T, Hontani M, Okubo K, Hirose S. Mutational analysis of action of mitochondrial fusion factor mitofusin-2. J Cell Sci. 2005;118(Pt 14):3153\u201361.","journal-title":"J Cell Sci"},{"issue":"19","key":"1602_CR131","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1212\/01.wnl.0000311275.89032.22","volume":"70","author":"GA Nicholson","year":"2008","unstructured":"Nicholson GA, Magdelaine C, Zhu D, Grew S, Ryan MM, Sturtz F, et al. Severe early-onset axonal neuropathy with homozygous and compound heterozygous MFN2 mutations. Neurology. 2008;70(19):1678\u201381.","journal-title":"Neurology"},{"issue":"4","key":"1602_CR132","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/jns.12145","volume":"20","author":"G Piscosquito","year":"2015","unstructured":"Piscosquito G, Saveri P, Magri S, Ciano C, Di Bella D, Milani M, et al. Mutational mechanisms in MFN2-related neuropathy: compound heterozygosity for recessive and semidominant mutations. J Peripher Nerv Syst. 2015;20(4):380\u20136.","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"1602_CR133","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1212\/WNL.0b013e3182242d4d","volume":"77","author":"JM Polke","year":"2011","unstructured":"Polke JM, Laur\u00e1 M, Pareyson D, Taroni F, Milani M, Bergamin G, et al. Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous Mitofusin 2 mutations. Neurology. 2011;77(2):168\u201373.","journal-title":"Neurology"},{"key":"1602_CR134","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1750-1172-8-106","volume":"8","author":"B Donadille","year":"2013","unstructured":"Donadille B, D\u2019Anella P, Auclair M, Uhrhammer N, Sorel M, Grigorescu R, et al. Partial lipodystrophy with severe insulin resistance and adult Progeria Werner syndrome. Orphanet J Rare Dis. 2013;8:106.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1602_CR135","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/cge.12262","volume":"85","author":"BK Chung","year":"2014","unstructured":"Chung BK, Gibson WT. Autosomal dominant PIK3R1 mutations cause SHORT syndrome. Clin Genet. 2014;85(3):228\u20139.","journal-title":"Clin Genet"},{"issue":"1","key":"1602_CR136","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000452082","volume":"8","author":"C Cunniff","year":"2017","unstructured":"Cunniff C, Bassetti JA, Ellis NA. Bloom\u2019s syndrome: clinical spectrum, molecular pathogenesis, and cancer predisposition. Mol Syndromol. 2017;8(1):4\u201323.","journal-title":"Mol Syndromol"},{"issue":"5","key":"1602_CR137","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ajhg.2017.09.017","volume":"101","author":"K Writzl","year":"2017","unstructured":"Writzl K, Maver A, Kova\u010di\u010d L, Martinez-Valero P, Contreras L, Satrustegui J, et al. De Novo mutations in SLC25A24 cause a disorder characterized by early aging, bone dysplasia, characteristic face, and early demise. Am J Hum Genet. 2017;101(5):844\u201355.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1602_CR138","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1056\/NEJMoa0706898","volume":"358","author":"MA Merideth","year":"2008","unstructured":"Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, et al. Phenotype and course of Hutchinson-Gilford Progeria syndrome. N Engl J Med. 2008;358(6):592\u2013604.","journal-title":"N Engl J Med"},{"key":"1602_CR139","doi-asserted-by":"crossref","unstructured":"J\u00e9ru I, Nabil A, El-Makkawy G, Lascols O, Vigouroux C, Abdalla E. Two decades after mandibuloacral dysplasia discovery: additional cases and comprehensive view of disease characteristics. Genes (Basel). 2021;12(10).","DOI":"10.3390\/genes12101508"},{"issue":"16","key":"1602_CR140","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/hmg\/ddg213","volume":"12","author":"AK Agarwal","year":"2003","unstructured":"Agarwal AK, Fryns JP, Auchus RJ, Garg A. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet. 2003;12(16):1995\u20132001.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"1602_CR141","doi-asserted-by":"publisher","first-page":"bvaa108","DOI":"10.1210\/jendso\/bvaa108","volume":"4","author":"S Magno","year":"2020","unstructured":"Magno S, Ceccarini G, Pelosini C, Ferrari F, Prodam F, Gilio D, et al. Atypical progeroid syndrome and partial lipodystrophy due to LMNA gene p.R349W mutation. J Endocr Soc. 2020;4(10):bvaa108.","journal-title":"J Endocr Soc"},{"issue":"11","key":"1602_CR142","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1002\/ajmg.a.34249","volume":"155a","author":"R Cabanillas","year":"2011","unstructured":"Cabanillas R, Cadi\u00f1anos J, Villameytide JA, P\u00e9rez M, Longo J, Richard JM, et al. N\u00e9stor-Guillermo Progeria syndrome: a novel premature aging condition with early onset and chronic development caused by BANF1 mutations. Am J Med Genet A. 2011;155a(11):2617\u201325.","journal-title":"Am J Med Genet A"},{"issue":"8","key":"1602_CR143","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/ng.2670","volume":"45","author":"MN Weedon","year":"2013","unstructured":"Weedon MN, Ellard S, Prindle MJ, Caswell R, Allen HL, Oram R, et al. An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet. 2013;45(8):947\u201350.","journal-title":"Nat Genet"},{"issue":"11","key":"1602_CR144","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1002\/ajmg.a.33690","volume":"152a","author":"LM Graul-Neumann","year":"2010","unstructured":"Graul-Neumann LM, Kienitz T, Robinson PN, Baasanjav S, Karow B, Gillessen-Kaesbach G, et al. Marfan syndrome with neonatal progeroid syndrome-like lipodystrophy associated with a novel frameshift mutation at the 3\u2019 terminus of the FBN1-gene. Am J Med Genet A. 2010;152a(11):2749\u201355.","journal-title":"Am J Med Genet A"},{"key":"1602_CR145","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.arr.2016.08.002","volume":"33","author":"AC Karikkineth","year":"2017","unstructured":"Karikkineth AC, Scheibye-Knudsen M, Fivenson E, Croteau DL, Bohr VA. Cockayne syndrome: clinical features, model systems and pathways. Ageing Res Rev. 2017;33:3\u201317.","journal-title":"Ageing Res Rev"},{"issue":"2","key":"1602_CR146","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ajhg.2014.12.011","volume":"96","author":"A Masotti","year":"2015","unstructured":"Masotti A, Uva P, Davis-Keppen L, Basel-Vanagaite L, Cohen L, Pisaneschi E, et al. Keppen-Lubinsky syndrome is caused by mutations in the inwardly rectifying K\u2009+\u2009channel encoded by KCNJ6. Am J Hum Genet. 2015;96(2):295\u2013300.","journal-title":"Am J Hum Genet"},{"issue":"11","key":"1602_CR147","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/ng.3103","volume":"46","author":"D Lessel","year":"2014","unstructured":"Lessel D, Vaz B, Halder S, Lockhart PJ, Marinovic-Terzic I, Lopez-Mosqueda J, et al. Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features. Nat Genet. 2014;46(11):1239\u201344.","journal-title":"Nat Genet"},{"issue":"7","key":"1602_CR148","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/ajmg.a.38246","volume":"173","author":"S Paolacci","year":"2017","unstructured":"Paolacci S, Bertola D, Franco J, Mohammed S, Tartaglia M, Wollnik B, et al. Wiedemann-Rautenstrauch syndrome: A phenotype analysis. Am J Med Genet A. 2017;173(7):1763\u201372.","journal-title":"Am J Med Genet A"},{"key":"1602_CR149","doi-asserted-by":"crossref","unstructured":"Gautheron J, Morisseau C, Chung WK, Zammouri J, Auclair M, Baujat G et al. EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular senescence. Elife. 2021;10.","DOI":"10.7554\/eLife.68445"},{"issue":"3","key":"1602_CR150","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ajhg.2015.07.009","volume":"97","author":"JJ Johnston","year":"2015","unstructured":"Johnston JJ, Sanchez-Contreras MY, Keppler-Noreuil KM, Sapp J, Crenshaw M, Finch NA, et al. A point mutation in PDGFRB causes Autosomal-Dominant Penttinen syndrome. Am J Hum Genet. 2015;97(3):465\u201374.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1602_CR151","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ajhg.2018.10.013","volume":"103","author":"L Xu","year":"2018","unstructured":"Xu L, Jensen H, Johnston JJ, Di Maria E, Kloth K, Cristea I, et al. Recurrent, activating variants in the receptor tyrosine kinase DDR2 cause Warburg-Cinotti syndrome. Am J Hum Genet. 2018;103(6):976\u201383.","journal-title":"Am J Hum Genet"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-025-01602-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-025-01602-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-025-01602-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:37:24Z","timestamp":1781609844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-025-01602-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":151,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1602"],"URL":"https:\/\/doi.org\/10.1007\/s11892-025-01602-5","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"31 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Elif A. Oral In the lipodystrophy space consults with and receives clinical trial and grant support from Amryt Pharmaceuticals now part of Chiesi, Regeneron Pharmaceuticals and Ionis Pharmaceuticals. She consults with Third Rock Ventures (now formed Marea Therapeutics) and Rejuvenate Inc. Grant money from PTC Therapeutics was also received in the last 2 years. She also has IP rights to metreleptin manufactured by Amryt Pharmaceuticals, now part of Chiesi and is entitled to royalty payments. Unrelated to lipodystrophy, Dr. Oral has ongoing clinical trial support from Novo Nordisk, Rhythm Pharmaceuticals, and Morphic Medical (formerly GI Dynamics). The other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"46"}}